EJNMMI Res. 2025 Sep 26;15(1):120. doi: 10.1186/s13550-025-01313-8.
ABSTRACT
BACKGROUND: We aimed to estimate 82Rb paediatric dosimetry based on adult biokinetic and prospectively acquired paediatric biokinetic data. Organ absorbed doses (OAD) and effective doses (E) were estimated using ICRP-103 based OLINDA/EXM.2.1 software. We extrapolated paediatric OAD and E from existing adult biokinetic data (OADp, Ab and Ep, Ab respectively). 82Rb EANM paediatric dosage card (PDC) cluster and the recommended administered activity were determined. Ten paediatric participants (M: F 7:3; mean age 8.8 ± 6.6y) underwent prospectively 3D-SiPM 82Rb PET/CT. Using PMOD software, source organs volumes were delineated to obtain source organ time activity curves and participant specific organ masses based on PET/CT data. Subject specific OAD (OADp and Ep respectively) were derived from original paediatric data.
RESULTS: 82Rb was assigned to the EANM PDC B-Cluster. Estimated ranges for Ep, Ab resp. Ep were 2.19E-02 ̶ 1.15E-03 resp. 9.62E-03 ̶ 1.04E-03 mSv/MBq. Ep, Ab resp. Ep with 10 MBq/kg and 5MBq/kg after a single 82Rb infusion was between 0.5 and 0.7 mSv resp. 0.4-0.8 mSv and 0.2-0.4 mSv. The most irradiated organs were the kidneys and the heart wall in infant and newborn group, followed by heart wall in the other age groups, hence, the small intestine, pancreas, lungs, adrenals, and rest of the gastrointestinal tract. 82Rb PET/CT was safe and well-tolerated by all participants.
CONCLUSIONS: We firstly provide original dosimetry data for the use of 82Rb PET/CT in the paediatric population, showing reasonably low radiation exposure, and confirming safety and tolerability of 82Rb PET/CT in this population.
PMID:41003908 | DOI:10.1186/s13550-025-01313-8
